Influence and mechanism of lung cavitation development on antiangiogenic therapy.

ABSTRACT:

Background

Antiangiogenic agent-treated patients usually develop cavitation in their lung lesions. The clinical significance of lung cavitation development during antiangiogenic therapy has not been determined yet. Herein, we evaluated the clinical outcomes of patients who developed tumor cavitation following apatinib treatment and explored the mechanisms.

Methods

In this study (Clinical Trial No. NCT03629691), 187 patients (77 lung cancer and 110 gastric adenocarcinoma patients) who had progressed or relapsed after undergoing at least two lines of systemic therapy in accordance with the NCCN guidelines for primary or metastatic lung tumors were treated with apatinib at a dosage of 250 mg per day between February 1, 2015 and May 19, 2017. The effect of lung cavitation develo

SUBMITTER: Jiang M 

PROVIDER: S-EPMC6749114 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature